Study of Cobimetinib in Participants With Solid Tumors
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
This non-randomized, open-label, study will determine the highest safe dose of cobimetinib,
how often it should be taken, how well participants with cancer tolerate cobimetinib and will
assess the pharmacokinetic effect of midazolam and dextromethorphan on the study drug.